$AGEN “objective responses observed in the ongoing Phase 1/2 trial, clinical benefits seen in underserved patient populations.” “the AACR presentations support AGEN1181’s place in the Agenus pipeline” just a positive presentation upcoming in a few days on a drug worth 10s of billions. Nothing to see here folks. Not until Monday that is!!!!!
13
13 Likes